GE Vernova T&D India Ltd (BOM:522275) Q4 2025 Earnings Call Highlights: Record Order Intake ...
Order Intake: INR29.9 billion in Q4, up 124% year-on-year from INR13.3 billion.
Revenue (Q4): INR11.5 billion, up 26% year-on-year from INR9.1 billion.
Revenue (FY24-25): INR42.9 billion, up 35% year-on-year from INR41.7 billion.
Order Backlog: INR126.6 billion as of March '25, doubled from INR62.7 billion as of March '24.
Profit Before Tax (Q4): INR2.5 billion, compared to INR1.01 billion in the previous year.
Profit Before Tax (FY24-25): INR8 billion, up from INR2.6 billion in FY23-24.
Cash and Cash Equivalents: INR10.5 billion as of March 31, up from INR2.8 billion as of March 31, '24.
Cash Generated (Q4): INR1.9 billion.
Cash Generated (FY24-25): INR8.3 billion.
EBITDA (Q4): INR2.5 billion, representing 21.9% of revenue.
EBITDA (FY24-25): INR8.1 billion, representing 19.1% of revenue.
Warning! GuruFocus has detected 1 Warning Sign with BOM:522275.
Release Date: May 23, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
GE Vernova T&D India Ltd (BOM:522275) reported significant revenue growth, with Q4 revenue increasing by 26% year-on-year to INR11.5 billion.
The company achieved a substantial increase in order intake, with Q4 orders reaching INR29.9 billion, up by 124% year-on-year.
The order backlog doubled to INR126.6 billion as of March 2025, indicating strong future demand.
The company announced a strategic investment of INR400 million to enhance manufacturing capabilities for HVDC technologies, positioning it well for future growth.
GE Vernova T&D India Ltd (BOM:522275) maintained a strong cash position, with cash and cash equivalents at INR10.5 billion as of March 31, 2025.
The company faces challenges in the supply chain due to global demand and political uncertainties, which could impact operations.
There is a risk of pricing stability in the transformer market, with limited room for further price increases.
The company has a significant portion of its order backlog tied to long-term projects, which may delay revenue realization.
The company's focus on product orders over turnkey projects could limit its market opportunities in certain segments.
The company has not yet secured any STATCOM projects in India, despite the growing importance of this technology in renewable energy integration.
Q: How much of the existing backlog of INR127 billion is executable within the next 18 months? A: Approximately INR85 billion of the order backlog is executable within 1.5 to 2 years. The remaining INR30 billion consists of longer-term projects with execution timelines of three to five years. Additionally, there are orders that are received and executed within the same financial year.
Q: Could you share the timeline for new HVDC projects, especially for FY26? A: We expect at least one to two HVDC projects to be funded during this year. The transmission committee is reviewing projects, and we anticipate some approvals soon.
Q: What explains the strong gross margin performance, and is it sustainable? A: The strong gross margin of 42% in Q4 was due to better pricing, a strategic shift towards product orders, and increased export revenue. While quarterly margins can vary, we aim to sustain the annual gross margin of 40.4% achieved this year.
Q: Is the new factory for HVDC components necessary to participate in upcoming domestic opportunities? A: While not a requirement, the new factory will enhance our competitiveness and local presence, which is beneficial for meeting Make in India criteria and improving customer confidence.
Q: How do you see the overall Total Addressable Market (TAM) growing for non-HVDC high-voltage and export segments? A: We anticipate a 20% CAGR in the non-HVDC space, driven by government plans and global energy transition trends. The export market is also expanding, with opportunities in Europe, Southeast Asia, and Africa.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
17 minutes ago
- Associated Press
Dimerco's June Freight Report Tracks Tariff Impacts, Capacity Strains, and Strategic Route Shifts
'We're seeing increased U.S. demand across sectors, but most of it is still moving by ocean. We expect airfreight to pick up mid-June as lead times tighten and spot options shrink.'— Kathy Liu, VP of Global Sales and Marketing at Dimerco Express Group TAIPEI, TAIWAN, June 3, 2025 / / -- The June 2025 Asia-Pacific Freight Market Report by Dimerco Express Group shows a freight landscape in flux, as policy shifts, regional bottlenecks, and trade realignments reshape global logistics strategies. The report highlights the continued ripple effects of U.S.–China tariff actions, rising air and ocean freight rates, and tightening space across key export hubs ahead of a potentially volatile summer shipping season. Key Market Developments: ----------------------------------- ⦿ Tariffs Driving Demand Shifts: U.S. tariffs on goods from China, combined with China's temporary easing of semiconductor tariffs, have triggered a surge of shipments as businesses race against a 90-day deadline. Companies across Vietnam, Taiwan, and South China are accelerating their shipping schedules, creating strain on already limited air and ocean freight capacities. ⦿ Ocean Freight Rates Climb as Carriers Cancel Sailings: With 8% of East-West sailings cancelled in May and peak season surcharges taking effect in June, carriers are leveraging limited capacity to push up rates. U.S.-bound ocean spot rates are expected to rise to as much as USD 8,000 per FEU this month. ⦿ Airfreight in Flux: Airfreight capacity remains limited in key regions, particularly Southeast Asia and Taiwan, as airlines redirect resources toward transpacific and Latin American routes. Simultaneously, spikes in orders and airline schedule adjustments are tightening capacity further from North Asia to the U.S. ⦿ European Congestion and U.S. Port Constraints: Ongoing labor shortages, strikes, and disruptions in inland waterways continue to delay European port operations. Meanwhile, North American ports face additional pressures from summer shipments of perishables and fewer available flights due to tariff-related adjustments. ⦿ Semiconductor Sector Realignment: China's suspension of retaliatory tariffs on U.S. semiconductors is boosting chip-related exports. Logistics providers are watching closely as the 90-day reprieve expires in August, potentially reshaping sourcing strategies and shipping flows again. 'Demand is shifting quickly, and the market is recalibrating week by week,' said Alvin Fuh, Vice President of Ocean Freight at Dimerco. 'Shippers are accelerating bookings to stay ahead of volatility, but capacity remains tight and unpredictable.' Kathy Liu, Vice President of Global Sales and Marketing, added, 'We're seeing increased U.S. demand across sectors, but most of it is still moving by ocean. We expect airfreight to pick up mid-June as lead times tighten and spot options shrink.' The June report offers lane-level snapshots and updated space forecasts for all major Asia-Pacific, North America, and Europe trade lanes, with insights designed to help shippers stay agile in a shifting policy and capacity environment. Click here to get access to the full June 2025 report, as well as review past reports. To schedule interviews with Dimerco's logistics experts, get in touch with Gitte (details below). About Dimerco -------------------- Dimerco Express Group integrates air and ocean freight, trade compliance, and contract logistics to enhance global supply chain effectiveness. The majority of Dimerco's logistics projects connect Asia's key manufacturing hubs with North America and Europe. From its roots as an air freight forwarder in Taiwan in 1971, Dimerco now operates 150+ offices, 80 contract logistics sites, and 200+ strategic partner agents worldwide. For more information, visit Gitte Willemsens CHARLIE PESTI +32 489 36 22 31 email us here Visit us on social media: LinkedIn Facebook YouTube X Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Bloomberg
37 minutes ago
- Bloomberg
Emerging-Market Stocks Gain as China Data Refuel Stimulus Hopes
Emerging-market stocks advanced for the first time in three days as a slump in China's factory activity increased bets on more economic stimulus. The benchmark MSCI EM index rose 0.4% after data showing China's manufacturing sector had its worst slump since September 2022, with higher tariffs taking a toll on smaller exporters. The onshore CSI 300 Index gained 0.3%, while a gauge of Chinese stocks listed in Hong Kong jumped 1.9%.
Medscape
37 minutes ago
- Medscape
Tocilizumab, Alone or With Methotrexate, Potent in Active RA
Subcutaneous tocilizumab, either as monotherapy or in combination with methotrexate, demonstrated greater efficacy than methotrexate alone and was well tolerated in patients with active rheumatoid arthritis (RA) who had an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). METHODOLOGY: Researchers conducted a phase 3 trial at 19 sites in China between July 2017 and August 2022 to evaluate the efficacy of subcutaneous tocilizumab, administered either as monotherapy or in combination with methotrexate, in 340 patients with moderate to severe active RA (mean age, 47.5 years; 86.5% women). The patients had a diagnosis of RA for ≥ 6 months, had received methotrexate for ≥ 12 weeks, experienced treatment failure with at least one csDMARD (including methotrexate), had at least six swollen joints and at least eight tender joints, and had either a high-sensitivity C-reactive protein level ≥ 4 mg/L or an erythrocyte sedimentation rate ≥ 28 mm/h. Patients were randomly assigned to receive tocilizumab-methotrexate combination therapy (n = 136), tocilizumab monotherapy with placebo (n = 136), or methotrexate monotherapy with placebo (n = 68) for 24 weeks. Tocilizumab (162 mg) was administered subcutaneously once every 2 weeks, and methotrexate (10-25 mg) was administered orally once every week. Patients achieving a Disease Activity Score in 28 joints of ≤ 3.2 after 24 weeks continued their randomly assigned treatment, whereas those with a score > 3.2 switched to unblinded tocilizumab-methotrexate treatment. The primary efficacy endpoint was the proportion of patients who achieved a ≥ 20% improvement in the American College of Rheumatology (ACR20) response criteria at 24 weeks, with long-term efficacy analyzed at 48 weeks and safety monitored for 56 weeks. TAKEAWAY: The ACR20 response rate at 24 weeks was higher in the tocilizumab-methotrexate combination therapy (52.9%) and tocilizumab monotherapy (50.0%) groups than in the methotrexate monotherapy group (25.0%), with significant differences of 27.9 and 25.0 percentage points, respectively ( P < .001 for both). < .001 for both). Long-term efficacy analysis at 48 weeks showed maintained or improved efficacy in patients continuing tocilizumab monotherapy or tocilizumab-methotrexate combination therapy, with an improved disease status in those who switched to unblinded tocilizumab-methotrexate treatment at 24 weeks. Tocilizumab was well tolerated as both monotherapy and in combination with methotrexate, with no new safety signals. IN PRACTICE: 'Subcutaneous tocilizumab, both as monotherapy and in combination with methotrexate, had clinically significant efficacy compared with methotrexate monotherapy in Chinese patients with moderate to severe active RA,' the authors wrote. SOURCE: This study was led by Tian Liu, MD, Peking University People's Hospital in Beijing, China. It was published online on May 19, 2025, in JAMA Network Open . LIMITATIONS: Only Chinese patients were included, thus limiting the generalizability of the findings. Researchers did not include imaging analysis. The recruitment was extended over a period of 4 years owing to the COVID-19 pandemic, which resulted in missing the efficacy assessments and tocilizumab administration in some patients. DISCLOSURES: This study received funding from and was conducted in collaboration with F. Hoffmann-La Roche Ltd. Three authors reported receiving grants from various pharmaceutical companies, including Roche. Two authors reported being employed by Roche (China) Holding.
